SRR1392725
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.426
- COAGULATION+0.346
- PANCREAS_BETA_CELLS+0.334
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.301
- ESTROGEN_RESPONSE_LATE+0.251
- MYOGENESIS+0.249
- BILE_ACID_METABOLISM+0.240
- XENOBIOTIC_METABOLISM+0.228
- INFLAMMATORY_RESPONSE+0.211
- TNFA_SIGNALING_VIA_NFKB+0.156
Top 10 suppressed
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.555
- DNA_REPAIR-0.499
- PROTEIN_SECRETION-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.430
- MITOTIC_SPINDLE-0.388
- CHOLESTEROL_HOMEOSTASIS-0.386
- MTORC1_SIGNALING-0.383
- E2F_TARGETS-0.372
- OXIDATIVE_PHOSPHORYLATION-0.371
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1475022 | GTEX | — | 0.971 |
| 2 | SRR1432765 | GTEX | — | 0.969 |
| 3 | SRR1455698 | GTEX | — | 0.961 |
| 4 | SRR1330346 | GTEX | — | 0.955 |
| 5 | SRR1473822 | GTEX | — | 0.954 |
| 6 | SRR1443955 | GTEX | — | 0.951 |
| 7 | SRR1476571 | GTEX | — | 0.945 |
| 8 | SRR1415732 | GTEX | — | 0.944 |
| 9 | SRR1444559 | GTEX | — | 0.942 |
| 10 | SRR1500617 | GTEX | — | 0.942 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.426 | Remibrutinib | — uncovered |
| COAGULATION | 0.346 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.334 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.301 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.251 | Idelalisib | — uncovered |
| MYOGENESIS | 0.249 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.228 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.211 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.156 | Inavolisib | — uncovered |
| HYPOXIA | 0.129 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.103 | Inavolisib | — uncovered |
| COMPLEMENT | 0.089 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.079 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.076 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.075 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.056 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.047 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.043 | Idelalisib | — uncovered |